De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient

Benefits of belatacept‐based immunosuppressive regimens in human immunodeficiency virus (HIV)–positive renal transplant recipients include avoidance of drug interactions between calcineurin inhibitors and highly active antiretroviral agents and decreased likelihood or severity of nonimmune toxicities such as new‐onset diabetes after transplant, hyperlipidemia and hypertension. We report a successful case of de novo belatacept at >18 mo from transplant in an HIV‐positive black man aged 50 years who received his first transplant from a living related kidney donor. To our knowledge, this case is the first reported of belatacept use in an HIV‐positive renal transplant recipient.